drugset / Trial / NCT00494091

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

NCT00494091

Phase 2 Completed 82 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.

Timeline

Start
2007-02
Primary completion
2011-05
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule 20 mg/m2 Intravenous
Subject Temsirolimus Small molecule 25 mg Intravenous

Indications